Pentagon Mandates Testosterone Testing for Male Troops Over 30

The U.S. Department of Defense has introduced compulsory testosterone testing for male troops aged 30 and above, a move that excludes women for now and has drawn criticism from health professionals. The policy aims to identify and treat low hormone levels to boost readiness, but experts question th…

By Felo News Desk · Published Sat, 19 Sep 2026 01:44:21 GMT

The U.S. Department of Defense announced new clinical guidance that requires all male service members who are 30 years old or older to undergo testosterone level testing. The directive, released in late September, follows a July memorandum by Defense Secretary Pete Hegseth that framed the program as a way to keep troops operating at their "absolute best." Women are not subject to the same mandatory screening at this time, though the Pentagon has indicated that a separate guideline for female personnel is under review.

What the New Guidance Requires

The guidance states that every eligible male soldier, sailor, airman, or Marine will receive a blood test to measure testosterone levels. Those who are younger than 30 may request testing if they believe they have symptoms related to hormone deficiency, but the program does not mandate it for them. If a test shows a low level, the service member is not automatically prescribed replacement therapy; instead, the decision to treat is left to the treating medical officer, who must consider the individual's medical history and future family plans.

The document also outlines practical considerations for administering testosterone in a deployed setting. Injectable testosterone must be stored at controlled room temperature and is classified as a controlled substance, requiring strict custody and accounting procedures. The guidance cautions that supply and continuity of treatment must be addressed before deployment rather than in theater.

Medical Community Response

Many clinicians and professional societies have expressed concern that the Pentagon’s approach departs from standard medical practice. In the United States, routine screening for testosterone deficiency is generally reserved for men who report symptoms such as low libido, erectile dysfunction, or depressed mood, and requires two separate blood tests to confirm a diagnosis. The new policy, by contrast, mandates testing for all men over 30 regardless of symptoms.

Experts also point out that the evidence for testosterone replacement improving energy, vitality, or cognitive function is weak. The guidance acknowledges this limitation, noting that the hormone’s proven benefits are mainly related to sexual function and bone density. Side effects, including a potential reduction in sperm count, are highlighted, and providers are instructed not to prescribe testosterone to men who plan to father children in the near future.

Context and Rationale

Defense Secretary Hegseth’s July statement framed low testosterone as a factor that could impair a soldier’s psychological and physical readiness. He argued that identifying and treating suboptimal hormone levels would strengthen performance and maximize force readiness. This view aligns with a broader public fascination with testosterone, fueled by men’s health influencers who tout the hormone as a way to boost energy and muscle mass.

However, the Pentagon’s guidance also reflects a cautious stance on the hormone’s use in combat environments. The memo notes that the controlled nature of testosterone raises supply, custody, storage, and continuity concerns that must be resolved before deployment. This practical perspective contrasts with Hegseth’s earlier rhetoric, which emphasized the hormone’s role in maintaining peak readiness.

Unresolved Questions and Next Steps

While the guidance clarifies the testing protocol for men, it leaves several issues open. The Pentagon has not yet determined whether female service members will be eligible for estrogen-based therapy as they enter perimenopause. Additionally, the policy does not specify how long a service member must maintain therapy once it is started, nor does it detail how the Department will manage the logistics of controlled substance storage in austere environments.

The Department has also stated that the female clinical practice guideline is under review and will be posted upon approval. Until that guideline is released, women will not receive mandatory hormone testing, though they may be evaluated on a case‑by‑case basis if they report symptoms of hormonal imbalance.

Medical experts continue to call for more robust evidence before the Pentagon expands hormone testing to a broader population. They suggest that the Department monitor outcomes closely and adjust the program based on real‑world data on effectiveness, safety, and operational impact.

Implications for Service Members

For the men who will be tested, the policy offers a potential pathway to address low testosterone, which can affect mood, sexual function, and bone health. However, the decision to treat remains discretionary, and the guidance emphasizes the importance of informed consent and consideration of future fertility plans.

Service members who are concerned about the policy should consult with their military healthcare providers to understand how the testing will be conducted, what the results mean, and what treatment options are available if a deficiency is identified. They should also be aware of the logistical requirements for storing and accounting for testosterone in the field.

Overall, the Pentagon’s new testing mandate reflects a tension between the desire to optimize troop readiness and the need to adhere to established medical standards and operational realities.

Key facts

Mandatory testosterone testing for male troops 30+
Women excluded for now, separate guideline pending
Policy departs from standard medical screening practices
Guidance highlights limited benefits and potential side effects
Logistical challenges for storing and accounting for testosterone in deployment

Why it matters

The policy could set a precedent for how the military manages hormone health, affecting the well‑being and readiness of thousands of service members. It also raises important questions about medical ethics, evidence‑based practice, and the logistics of controlled substances in combat zones.

Frequently asked questions

Who will be tested under the new policy?

All male service members who are 30 years old or older will receive a blood test for testosterone levels. Younger men may request testing if they have symptoms.

Will women be required to undergo hormone testing?

No. Women are not subject to mandatory testing at this time, but a separate guideline for female personnel is under review.

What happens if a service member’s testosterone level is low?

The individual is not automatically prescribed replacement therapy; treatment decisions are made by the treating medical officer, taking into account medical history and future fertility plans.

What are the logistical concerns for testosterone use in the field?

Injectable testosterone must be stored at controlled room temperature, is a controlled substance requiring strict custody and accounting, and supply continuity must be addressed before deployment.